|1.||Yao, Z: 3 articles (11/2001 - 01/2001)|
|2.||McPherson, B C: 3 articles (11/2001 - 01/2001)|
|3.||Shinmura, Ken: 2 articles (01/2004 - 11/2002)|
|4.||Bolli, Roberto: 2 articles (01/2004 - 11/2002)|
|5.||Chai, Wei: 1 article (02/2014)|
|6.||Gao, Changjun: 1 article (02/2014)|
|7.||Zhao, Xiaoyong: 1 article (02/2014)|
|8.||Yang, Lu: 1 article (02/2014)|
|9.||Sun, Meiyan: 1 article (02/2014)|
|10.||Ding, Qian: 1 article (02/2014)|
07/01/1996 - "This was true even at doses of BW373U86 which produced convulsions. "
09/01/1994 - "The highest dose of BW373U86 examined (1.78 mg/kg) produced convulsions in one monkey. "
11/01/1993 - "Pretreatment with a single injection of BW373U86 (3.2, 10.0, 32.0 or 100 mg/kg) produced a dose-related reduction in the capacity of BW373U86 to induce a second convulsion. "
11/01/1993 - "Doses of BW373U86 that increased MSL often produced tremors and/or convulsions immediately after administration. "
11/01/1993 - "A dose of 3.2 mg/kg of midazolam completely eliminated convulsions induced by BW373U86. "
|2.||Myocardial Stunning (Stunned Myocardium)
11/01/2002 - "By using conscious rabbits (n = 120) in this study, we found that the delta-opioid receptor agonist (+/-)-4-[(alpha-R*)-alpha-[(2S*,5R*)-4-allyl-2,5-dimethyl-1-piperazinyl]-3-hydroxybenzyl]-N,N-diethylbenzamide (BW-373U86) induced late PC against myocardial stunning 24 h after treatment and that this effect was abolished by the selective cyclooxygenase-2 (COX-2) inhibitors N-[2-(cyclohexyloxy)4-nitrophenyl]methanesulfonamide (NS-398) and celecoxib. "
|3.||Brain Injuries (Brain Injury)
02/01/2014 - "The aim of this study was to investigate whether the DOR agonist BW373U86 conferred neuroprotection following ACA when given after resuscitation and to determine the long-term effects of chronic BW373U86 treatment on ACA-elicited brain injury. "
02/01/2014 - "Delta opioid receptor agonist BW373U86 attenuates post-resuscitation brain injury in a rat model of asphyxial cardiac arrest."
11/01/2001 - "Both preconditioning and BW373U86 activated the PKC delta isoform of particulate fraction before simulated ischemia without effect on total and cytosolic fractions. "
05/01/2008 - "These findings indicate that BW373U86 and Dynorphin A exerted distinct neuroprotection against ischemia via opioid-independent and -dependent mechanisms, respectively. "
04/16/2004 - "Rats were treated with the nonselective opioid agonist, morphine (MOR, 0.3 mg/kg), the delta-selective opioid agonist BW373U86 (BW, 1 mg/kg), or the GSK inhibitors, SB21 (0.6 mg/kg) or SB41(1.0 mg/kg), either 10 minutes before ischemia or 5 minutes before reperfusion. "
01/16/2001 - "Like PC, morphine and BW373U86 increased free radical production 2-fold before ischemia (0.35+/-0.10, n=6*; 0.41+/-0.08, n=4* versus controls, 0.15+/-0.05, n=8, arbitrary units). "
01/16/2001 - "PC with 10 minutes of simulated ischemia before 10 minutes of reoxygenation or morphine (1 micromol/L) or BW373U86 (10 pmol/L) infusion for 10 minutes followed by a 10-minute drug-free period before 1 hour of ischemia and 3 hours of reoxygenation reduced cell death to the same extent (*P:<0.05) (PC, 20+/-1%, n=7*; morphine, 32+/-4%, n=8*; BW373U86, 21+/-6%; controls, 52+/-5%, n=8). "
02/01/1998 - "BW373U86 did not alter shock-evoked somatomotor reflexes and had few effects on the development or retention of Pavlovian conditioned heart rate discrimination. "
11/01/1993 - "Taken together, these findings indicate that BW373U86 has a delta agonist profile in the squirrel monkey; however, its antinociceptive effects in the shock titration procedure may be due to its toxic effects."
11/01/1993 - "A novel delta opioid agonist, BW373U86, in squirrel monkeys responding under a schedule of shock titration."
02/01/1998 - "BW373U86 was more potent in increasing signaled than unsignaled shock-evoked tachycardia, suggesting release of an endogenous substance (e.g., a delta-opioid) because of the Pavlovian conditioning contingency."
|2.||delta Opioid Receptors (delta Opioid Receptor)
|3.||Cyclooxygenase 2 (Cyclooxygenase-2)
|7.||Morphine (MS Contin)
|8.||4- (alpha- (4- allyl- 2,5- dimethyl- 1- piperazinyl)- 3- methoxybenzyl)- N,N- diethylbenzamide
|9.||N- (2- cyclohexyloxy- 4- nitrophenyl)methanesulfonamide